Premium
Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21
Author(s) -
Kimmich Christoph R.,
Terzer Tobias,
Benner Axel,
Hansen Timon,
Carpinteiro Alexander,
Dittrich Tobias,
Veelken Kaya,
Jauch Anna,
Huhn Stefanie,
Basset Marco,
Goldschmidt Hartmut,
MüllerTidow Carsten,
Schönland Stefan O.,
Hegenbart Ute
Publication year - 2021
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.26191
Subject(s) - daratumumab , lenalidomide , dexamethasone , medicine , al amyloidosis , multiple myeloma , gastroenterology , oncology , surgery , immunology , immunoglobulin light chain , antibody